Dmitrii Ishutin
United Kingdom
7m
Biotech (Intellia Therapeutics) — The “moonshot” in the mix. Biotech stayed choppy this month, and NTLA remains a catalyst-driven name where headlines can swing prices fast. Thesis unchanged: I’m holding for clinical progress and partnership momentum rather than trying to trade every wiggle. Up 40% MTD, really nice gain. Payments (PayPal) — PYPL spent most of the month consolidating. The watch items into year-end are user engagement, take-rate stability, and cost discipline. If e-commerce volumes perk up into the holidays, PYPL can re-rate; if not, I’m happy letting buybacks and margin work compound quietly in the background. Consumer (Jack in the Box) — Turnaround stories zig-zag, and JACK is no exception. I’m focused on same-store sales and margin commentary rather than headlines about closures or footprint tweaks. Any sign of traffic stabilising + cost control tends to get rewarded quickly in this space. Real assets / REITs (Primary Health Properties + SEGRO) — Rates remain the big driver. PHP is my “defensive income” tilt (GP surgeries, long leases), while SEGRO leans to logistics and structural demand. If yields ease, both can lift; if rates stay sticky, I still like the income/resilience profile here and will be patient. Rates trade (TMF – long-duration Treasuries) — TMF is my macro hedge. It benefits most when inflation cools and rate expectations drift lower; it’s volatile when “higher-for-longer” chatter dominates. I’m using it against risk assets rather than a day-to-day trading vehicle. Nice 10% growth MTD and a break-out above the 200-day MA - hopefully becoming a catalyst for future growth.
null
.